Cargando…

Loss of GPER identifies new targets for therapy among a subgroup of ERα-positive endometrial cancer patients with poor outcome

BACKGROUND: The G protein-coupled oestrogen receptor, GPER, has been suggested as an alternative oestrogen receptor. Our purpose was to investigate the potential of GPER as a prognostic and predictive marker in endometrial carcinoma and to search for new drug candidates to improve treatment of aggre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krakstad, C, Trovik, J, Wik, E, Engelsen, I B, Werner, H M J, Birkeland, E, Raeder, M B, Øyan, A M, Stefansson, I M, Kalland, K H, Akslen, L A, Salvesen, H B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3349187/ https://www.ncbi.nlm.nih.gov/pubmed/22415229 http://dx.doi.org/10.1038/bjc.2012.91

Ejemplares similares

Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma
por: Engelsen, I B, et al.
Publicado: (2008)

High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer
por: Mauland, K K, et al.
Publicado: (2011)

KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer
por: Birkeland, E, et al.
Publicado: (2012)

Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses
por: Bredholt, Geir, et al.
Publicado: (2015)

Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer
por: Stefansson, Ingunn M., et al.
Publicado: (2015)

Lipocalin 2 expression is associated with aggressive features of endometrial cancer
por: Mannelqvist, Monica, et al.
Publicado: (2012)

Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas
por: Haldorsen, I S, et al.
Publicado: (2014)

Integrated Genomic Analysis of the 8q24 Amplification in Endometrial Cancers Identifies ATAD2 as Essential to MYC-Dependent Cancers
por: Raeder, Maria B., et al.
Publicado: (2013)

High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors
por: Engerud, H, et al.
Publicado: (2014)

Switch in FOXA1 Status Associates with Endometrial Cancer Progression
por: Tangen, Ingvild Løberg, et al.
Publicado: (2014)

Stathmin Protein Level, a Potential Predictive Marker for Taxane Treatment Response in Endometrial Cancer
por: Werner, Henrica M. J., et al.
Publicado: (2014)

Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival
por: Mauland, Karen Klepsland, et al.
Publicado: (2016)

High-Throughput Mutation Profiling of Primary and Metastatic Endometrial Cancers Identifies KRAS, FGFR2 and PIK3CA to Be Frequently Mutated
por: Krakstad, Camilla, et al.
Publicado: (2012)

ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma
por: Krakstad, Camilla, et al.
Publicado: (2015)

Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene
por: Hoivik, Erling A., et al.
Publicado: (2014)

Androgen receptor as potential therapeutic target in metastatic endometrial cancer
por: Tangen, Ingvild Løberg, et al.
Publicado: (2016)

Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer
por: Kusonmano, Kanthida, et al.
Publicado: (2018)

Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients
por: Berg, Anna, et al.
Publicado: (2014)

PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer
por: Mjos, Siv, et al.
Publicado: (2017)

HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
por: Halle, Mari Kyllesø, et al.
Publicado: (2018)

Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients
por: Tangen, Ingvild L, et al.
Publicado: (2017)

The Co-Expression of Estrogen Receptors ERα, ERβ, and GPER in Endometrial Cancer
por: Hojnik, Marko, et al.
Publicado: (2023)

Independent prognostic importance of microvessel density in endometrial carcinoma.
por: Salvesen, H. B., et al.
Publicado: (1998)

Stathmin expression associates with vascular and immune responses in aggressive breast cancer subgroups
por: Askeland, Cecilie, et al.
Publicado: (2020)

Whole‐Volume Tumor MRI Radiomics for Prognostic Modeling in Endometrial Cancer
por: Fasmer, Kristine E., et al.
Publicado: (2020)

MRI-assessed tumor-free distance to serosa predicts deep myometrial invasion and poor outcome in endometrial cancer
por: Dybvik, Julie Andrea, et al.
Publicado: (2022)

Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers
por: Berg, Anna, et al.
Publicado: (2017)

Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients
por: Mauland, Karen Klepsland, et al.
Publicado: (2017)

Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease
por: Lien, Hilde E., et al.
Publicado: (2023)

Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer
por: Nalwoga, H, et al.
Publicado: (2010)

Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival
por: Kamal, A M, et al.
Publicado: (2016)

L1CAM expression in endometrial carcinomas: an ENITEC collaboration study
por: van der Putten, Louis JM, et al.
Publicado: (2016)

Corrigendum to “Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease” [EBioMedicine 92 (2023) 104595]
por: Lien, Hilde E., et al.
Publicado: (2023)

Differential expression of DHHC9 in microsatellite stable and instable human colorectal cancer subgroups
por: Mansilla, F, et al.
Publicado: (2007)

Investigation of chromosome 1q reveals differential expression of members of the S100 family in clinical subgroups of intracranial paediatric ependymoma
por: Rand, V, et al.
Publicado: (2008)

Infrared spectroscopy with multivariate analysis to interrogate endometrial tissue: a novel and objective diagnostic approach
por: Taylor, S E, et al.
Publicado: (2011)

Preoperative Tumor Size at MRI Predicts Deep Myometrial Invasion, Lymph Node Metastases, and Patient Outcome in Endometrial Carcinomas
por: Ytre-Hauge, Sigmund, et al.
Publicado: (2015)

A clinically applicable molecular-based classification for endometrial cancers
por: Talhouk, A, et al.
Publicado: (2015)

Plasma growth differentiation factor-15 is an independent marker for aggressive disease in endometrial cancer
por: Engerud, Hilde, et al.
Publicado: (2019)

Preoperative 18F-FDG PET/CT tumor markers outperform MRI-based markers for the prediction of lymph node metastases in primary endometrial cancer
por: Fasmer, Kristine E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3pbqahfl8931u3v2p95kmc1qsl